Get Ready for the Crypto Craze: Institutions Set to Embrace Digital Currency in 2023 – According to Goldman Sachs!

Goldman Sachs and the Evolution of Cryptocurrency Markets Breaking Down the Report Last week, Goldman Sachs released a report that sent shockwaves through the cryptocurrency world. In the report, they boldly stated that 2023 would be the year when cryptocurrency markets would evolve further and be adopted by institutions. According to Goldman Sachs, the institutionalization…

Read More

Maximizing Business Success: Police Sacco Ordered to Cease Mandatory Deductions

Police SACCO directed to stop compulsory deductions Background Parliament has directed the Uganda Police Forces’ Exodus Savings and Credit Cooperative (SACCO) to stop mandatory deduction of personnel salaries as savings. The Committee on Defence and Internal Affairs discovered that the SACCO’s management is violating the Cooperatives Societies Act by denying them the option of voluntary…

Read More

Breaking News: Wearable Devices Secures Deal with Qualcomm for Enhanced Technology Advancements

This Collaboration Aims to Transform XR Industry with Touchless Control YOKNEAM ILLIT, ISRAEL, Feb. 12, 2024 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced a collaboration agreement with Qualcomm Technologies, Inc. This collaboration will help…

Read More

X4 Pharmaceuticals Announces Exciting Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Issues Inducement Awards to New Employees It’s always a big moment when a company announces inducement awards to new employees, and X4 Pharmaceuticals is no exception. On August 30, 2024, the company revealed that it had issued inducement awards under the 2019 Inducement Equity Incentive Plan. These awards are designed to attract top…

Read More

Revolutionary Results: Mira Pharmaceuticals’ Ketamir-2 Outperforms FDA-Approved Gabapentin by 60% in Treating Chemotherapy-Induced Neuropathic Pain

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy New Findings to Be Presented at the Pain Therapeutics Summit MIAMI, FL / ACCESSWIRE / October 28, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, announces compelling new preclinical findings showing that Ketamir-2, a novel oral ketamine analog, achieves 60% greater…

Read More